Skip to main content
New biotech raises $6.5M to advance stem cell therapy for Parkinson's

A funding round brought in $6.5 million for Aspen Neuroscience, a newly launched biotech that is developing an autologous neuron replacement for patients with Parkinson's disease. Aspen will need to raise additional capital via a Series A funding round to advance its lead candidates through midstage trials, though.

Full Story: